Patisiran is a first-of-its kind RNA interference (RNAi)-based therapy designed to reduce levels of both WT and mutant transthyretin (TTR) for the treatment of patients with hereditary transthyretin-mediated amyloidosis, a congenital neurological and cardiac disorder [109]. The gene discussed is TTR; the disease is amyloidosis.